<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735511</url>
  </required_header>
  <id_info>
    <org_study_id>APA-GC-2018-HNZL</org_study_id>
    <nct_id>NCT03735511</nct_id>
  </id_info>
  <brief_title>A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma</brief_title>
  <official_title>A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LinkDoc Technology (Beijing) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the efficacy and safety of apatinib in the treatment of
      patients with gastric carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a real-world non-interventional retrospective study and will collect the
      original medical records of patients with gastric carcinoma treated with apatinib from 2015
      to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of
      treatments, tumor biological characteristics and adverse events will be analyzed to evaluate
      the efficacy and safety of apatinib and explore the risk factors of prognosis in patients
      with gastric carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2015-2018</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>2015-2018</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>2015-2018</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>2015-2018</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <enrollment type="Actual">270</enrollment>
  <condition>Gastric Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients who were pathologically or cytologically diagnosed gastric carcinoma and
        treated by apatinib.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically or cytologically confirmed gastric or residual gastric or
             gastroesophageal junction carcinoma;

          2. Patients received apatinib treatment at least once.

        Exclusion Criteria:

        1. No specific exclusion criteria in this real world study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

